Glaucoma is a ripe opportunity for drug developers. Generics litter the field, yet it’s a roughly $5 billion market that will only grow with an aging population. What’s more, nothing out there cures the disease. Patients typically take eye drops, chronically, for the rest of their lives.
In other words, there’s room for innovation. That’s what led successful ophthalmology executive Vicente Anido Jr. to Bedminster, NJ-based Aerie Pharmaceuticals, one of the leading contenders with a new approach to the disorder.
Inotek Pharmaceuticals is about to make its Nasdaq debut, but not at the price it was shooting for.
The Lexington, MA-based company priced its IPO late Tuesday, selling 6.67 million shares at $6 apiece and raising about $40 million before discounts due to underwriters.
Your eye could someday house its own high-tech information center, tracking important changes and letting you know when it’s time to see an eye doctor.
University of Washington engineers have designed a low-power sensor that could be placed permanently in a person’s eye to track hard-to-measure changes in eye pressure. The sensor would be embedded with an artificial lens during cataract surgery and would detect pressure changes instantaneously, then transmit the data wirelessly using radio frequency waves.
